P
GSK icon

&Partners’s GSK GSK Stock Holding History

&Partners’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.31M Sell
60,115
-33,190
-36% -$1.8M 0.02% 689
2025
Q4 		$4.58M Sell
93,305
-2,485
-3% -$116K 0.02% 525
2025
Q3 		$4.13M Buy
95,790
+7,526
+9% +$294K 0.03% 484
2025
Q2 		$3.39M Buy
88,264
+49,338
+127% +$1.89M 0.03% 474
2025
Q1 		$1.51M Buy
38,926
+273
+0.7% +$9.99K 0.02% 648
2024
Q4 		$1.3M Buy
38,653
+15,441
+67% +$556K 0.02% 663
2024
Q3 		$936K Buy
23,212
+7,336
+46% +$300K 0.02% 591
2024
Q2 		$611K Buy
15,876
+9,077
+134% +$382K 0.03% 476
2024
Q1 		$299K Buy
+6,799
New +$280K 0.04% 365

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

&Partners's GSK Position: Q1 2026 in Review

&Partners reduced its GSK (GSK) stake by 36% in Q1 2026, selling an estimated $1.8M and leaving 60,115 shares worth $3.31M. The position accounts for 0.02% of the portfolio, ranked #689.

&Partners first reported a position in GSK in Q1 2024 and has held it in 9 quarters since. The position peaked at $4.58M in Q4 2025. 1,032 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • &Partners held 60,115 shares of GSK worth $3.31M as of Q1 2026.
  • &Partners sold 33,190 GSK shares in Q1 2026, an estimated $1.8M.
  • GSK made up 0.02% of &Partners's portfolio in Q1 2026, its #689 holding.
  • &Partners first reported a position in GSK in Q1 2024 and has held it in 9 quarters since.
  • &Partners's GSK position peaked at $4.58M in Q4 2025.
  • 1,032 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.